WASHINGTON, March 16 -- Sen. Maggie Hassan issued the following press release:
Following two years of pressure from U.S. Senator Maggie Hassan (D-NH), Ranking Member of the Senate Finance Subcommittee on Health Care, a major pharmaceutical company has ended its decades-long practice of pairing egregious price hikes and monopoly protection by allowing a low-cost generic alternative for an asthma inhaler commonly used by children to enter the market.
Read Senator Hassan's new investigative report HERE (https://www.hassan.senate.gov/imo/media/doc/flovent_investigation_report.pdf).
"For decades, GlaxoSmithKline (GSK) has blocked competitors and increased prices on a life-saving asthma inhaler to unconscionable levels, with children, families...